Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00001814 · ClinicalTrials.gov registry record

Genetic Analysis of Inherited Urologic Malignant Disorders: Collection of Samples

A clinical trial, sponsored by National Cancer Institute (NCI).

Completed
Registry status
600
Enrollment target

NCT00001814: Completed study, sponsored by National Cancer Institute (NCI).

NCT00001814 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 600 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00001814 has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
600 participants
Enrollment target

Study Summary

Investigation of the causes of genetic defects relating to hereditary urologic malignancies will be undertaken. These rare disorders result from inherited or newly arising mutations in genes involved in the development and function of different organ systems. As specific disease syndromes are recognized and the responsible genes identified, mutations in individual families can be identified. Correlation of mutation sites with clinical information will help determine how specific gene segments encode important functional protein domains. Families with urologic malignant disorders of known or suspected genetic basis will be enrolled. Genetic linkage studies will include all available family members, while gene sequence analysis will be performed on affected individuals. Unaffected family members or unrelated normal individuals will serve as controls. The family members will be identified by the proband or proband's parent when the initial pedigree is taken. Subjects considered by the investigators to be appropriate for linkage studies will be invited to participate by the local genetics provider or by the investigators, who will then connect these members to their own local providers for enrollment. In our studies of inherited urologic malignant disorders, there may be individuals from renal cancer families who do not undergo clinical evaluation for the presence of an inherited urologic malignant disorder at the National Institutes of Health because of their health problems, geographical location, or personal preference. Even though these individuals do not undergo a clinical evaluation of their suspected inherited urologic malignant disorder at the National Institutes of Health, they may have rare diseases that are extremely important to study. Therefore, we intend to collect blood samples for genetic studies from these individuals to facilitate linkage analysis and disease gene identification. Samples will be collected either by the individual's physician and sent

Trial Details

FieldValue
Enrollment Target 600 participants
Start Date 1999-04
Est. Completion 2001-01
National Cancer Institute (NCI)

3,257 total trials

What the finished NCT00001814 record still lists

NCT00001814 is an observational study that tracks outcomes without assigning an intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 0 interventions.

NCT00001814 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00001814 about?

NCT00001814 is a clinical study titled "Genetic Analysis of Inherited Urologic Malignant Disorders: Collection of Samples". Investigation of the causes of genetic defects relating to hereditary urologic malignancies will be undertaken. These rare disorders result from inherited or newly arising mutations in genes involved in the development and function of different organ systems. As specific disease syndromes are recogn...

What is the current status of trial NCT00001814?

This trial is currently completed. The enrollment target is 600 participants. The study started on 1999-04. Estimated completion is 2001-01.

Who is sponsoring clinical trial NCT00001814?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00004317 · 600 participants · Phase 4

    Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis

  • NCT00209235 · 600 participants · NA

    Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments

  • NCT01473784 · 600 participants · NA

    Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck

  • NCT01866371 · 600 participants

    High Resolution Retinal Imaging

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00001814, the US trial registry maintained by the National Library of Medicine. NCT00001814 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.